ApplyBlast uses AI to match you with the right jobs, tailor your resume and cover letter, and apply automatically so you can land your dream job faster.

Features

Auto Apply Resume Optimizer Cover Letter Optimizer Interview Prep

Company

Social Media

Need Help?

team@applyblast.com

Vice President, Analytical Development & Quality Control at Revolution Medicines - ApplyBlast

Vice President, Analytical Development & Quality Control

Revolution Medicines

6 months ago

3.5 on Glassdoor

United States

Onsite

Full Time

Senior

1 applicant

View Job Listing

Apply to 100+ jobs

About this role

A Vice President, Analytical Development & Quality Control at Revolution Medicines leads the vision, strategy, and execution of analytical development and QC across the company's growing oncology portfolio. The role involves shaping analytical strategy, ensuring regulatory readiness, and managing external networks to support late-stage development and global commercialization.

Skills

Qualifications

PhD (preferred) or MSc in Analytical Chemistry, Pharmaceutical Sciences, or related field18+ years of industry experience with significant leadership in analytical development and QCProven track record supporting late-stage development and global regulatory filings (IND/NDA/MAA/JNDA)Deep expertise in GMP, quality systems, and global regulatory expectations (FDA, EMA, ICH)Extensive experience managing external analytical networks (CDMOs, CTLs)

About Revolution Medicines

revmed.com

Headquarters

Redwood City, California, United States

Company Size

201-500 employees

Founded

2014

View Profile

Revolution Medicines (RevMed) is a biopharmaceutical company dedicated to discovering, developing, and delivering novel targeted medicines for patients with cancer. Their mission focuses specifically on "revolutionizing treatment for patients with RAS‑addicted cancers" through precision-targeted therapies. The company emphasizes a science-driven, end-to-end approach from discovery to delivery. RevMed brands its team as "Revolutionaries" committed to transforming outcomes for people with RAS‑driven tumors.